Cadrenal Therapeutics, Inc. — Form 8-K
Filed September 29, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 72/100
What the filing says
Cadrenal's Board approved Amendment No. 2 to its 2022 Successor Equity Incentive Plan on September 24, 2026, increasing the maximum share reserve available for grants by 323,542 shares to a new total of 1,000,000 shares (from ~676,458 shares previously). The amendment also sets the Incentive Stock Option limit at 1,000,000 shares. Amendment is effective upon stockholder approval, which is required under applicable law.
Why this rating
Significant equity dilution risk for a $24.9M market-cap company. Adding 323k shares to incentive pool (~3.2% of likely outstanding count) is material and signals runway concerns, but routine for pre-revenue biotech.
Price action (we called it neutral)
before filing · preread $1.09 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from September 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.